Researchers discover enzyme behind breast cancer mutations

February 6, 2013

Researchers at the University of Minnesota have uncovered a human enzyme responsible for causing DNA mutations found in the majority of breast cancers. The discovery of this enzyme – called APOBEC3B – may change the way breast cancer is diagnosed and treated.

The findings from a team of researchers led by Reuben Harris, Ph.D., associate professor of biochemistry, molecular biology and biophysics and also a researcher at the Masonic Cancer Center, University of Minnesota, are published in the latest edition of Nature.

"We strongly believe this discovery will change the way mutations in cancer are viewed and, hopefully, it will allow cancer researchers to develop new treatments approaches that can prevent these mutations before they become harmful," said Harris.

Harris' quest to learn more about mutations in cancer initially began with . This previous work by Harris' lab and others indicated that APOBEC3B and related enzymes function normally to protect from like HIV-1.

During these studies, Harris' team developed specific tests to quantify the expression of each of the seven APOBEC3 genes, including APOBEC3B.

Harris and his team were able to apply these tests to the problem of mutation in breast cancer, showing only APOBEC3B is over-expressed in patients' breast cancer cell lines and tumors.

" are absolutely essential for ," said Harris. "Our experiments showed the APOBEC3B enzyme causes mutations in the genome of . From this, we were able to reasonably conclude that the APOBEC3B is a key influencer in breast cancer."

However, Harris points out that APOBEC3B appears to be a biological "double-edged sword." It protects some cells from viruses such as HIV-1 yet produces mutations giving rise to cancer in others.

Harris stresses the need for additional research. If further studies confirm that high APOBEC3B levels indicate the early presence of breast cancer, a simple blood test could be a strategy for early detection.

Another goal for Harris is finding a way to block APOBEC3B from causing mutation, just as sunscreen prevents sun from causing mutations leading to melanoma. His collaborative HIV studies are already pointing toward such drug possibilities.

"Our next steps will focus on the connections between high levels of APOBEC3B, age and other genetic risk factors that are known markers. Ultimately, we hope our discovery leads to better therapeutic outcomes for patients," said Harris.

Explore further: Landscape of cancer genes and mutational processes in breast cancer

Related Stories

Landscape of cancer genes and mutational processes in breast cancer

May 16, 2012
In a study published today in Nature, researchers describe nine new genes that drive the development of breast cancer. This takes the tally of all genes associated with breast cancer development to 40.

UK considers preventative drugs for breast cancer (Update)

January 15, 2013
Britain's National Health Service may soon offer women at high risk of developing breast cancer drugs normally used to treat the disease as a prevention strategy.

Gene responsible for many spontaneous breast cancers identified

October 2, 2012
Cancerous tumors contain hundreds of mutations, and finding these mutations that result in uncontrollable cell growth is like finding the proverbial needle in a haystack. As difficult as this task is, it's exactly what a ...

Study finds new member of the breast-cancer gene network

February 22, 2012
The infamous BRCA genes do not act alone in causing cancer; there is a molecular syndicate at work preventing the way cells normally repair breaks in DNA that is at the root of breast cancer. But finding all of the BRCA molecular ...

Recommended for you

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Egleton
1 / 5 (1) Feb 07, 2013
Cancer is a mitochondrial disease.
http://vimeo.com/...54542349

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.